Here's how NCBI.NLM.NIH.GOV makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NCBI . NLM . NIH . GOV {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Ncbi.nlm.nih.gov Make Money
  6. Keywords
  7. Topics
  8. Social Networks
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. Hosting Providers
  13. CDN Services

We began analyzing https://pmc.ncbi.nlm.nih.gov/articles/PMC9630162/, but it redirected us to https://pmc.ncbi.nlm.nih.gov/articles/PMC9630162/. The analysis below is for the second page.

Title[redir]:
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial - PMC
Description:
Capivasertib, an AKT inhibitor, added to fulvestrant, was previously reported to improve progression-free survival in women with aromatase inhibitor-resistant oestrogen receptor (ER)-positive, HER2-negative advanced breast cancer. The benefit ...

Matching Content Categories {πŸ“š}

  • Science
  • Education
  • Health & Fitness

Content Management System {πŸ“}

What CMS is ncbi.nlm.nih.gov built with?

Custom-built

No common CMS systems were detected on Ncbi.nlm.nih.gov, and no known web development framework was identified.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of ncbi.nlm.nih.gov audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Ncbi.nlm.nih.gov Make Money? {πŸ’Έ}

We don’t know how the website earns money.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Ncbi.nlm.nih.gov might have a hidden revenue stream, but it's not something we can detect.

Keywords {πŸ”}

participants, capivasertib, survival, cancer, pathway, fulvestrant, subgroup, doi, expanded, pathwayaltered, analysis, breast, placebo, trial, nonaltered, progressionfree, data, akt, advanced, pikaktpten, inhibitor, tumours, received, pubmed, results, tumour, months, google, scholar, faktion, treatment, group, ngs, identified, testing, pikca, primary, pten, pmc, original, phase, study, patients, therapy, mutations, status, population, article, hernegative, erpositive,

Topics {βœ’οΈ}

pi3k/akt/pten pathway-altered er-positive pi3k/akt/pten pathway-altered status pi3k/akt/pten pathway-altered tumours expanded pi3k/akt/pten pathway-altered pi3k/akt/pten pathway activation pi3k/akt/pten signalling pathway pi3k/akt/pten pathway altered pi3k/akt/pten pathway-altered pi3k/akt/pten pathway alterations pi3k/akt/pten pathway inhibitor pi3k/akt/pten pathway deregulation Ξ±-isoform-specific pi3k inhibitor aromatase inhibitor-resistant er-positive her2-negative breast cancer her2-negative breast cancers local investigator-confirmed er-positive pi3k/akt/pten pathway interactive web-response system ngs-identified pathway-altered subgroup human breast tumours improve progression-free survival investigator-assessed progression-free survival detects single-nucleotide variations analysing progression-free survival hormone receptor-positive hormone-receptor-positive detect single-nucleotide variations pmc beta search advanced breast cancer cancer genome atlas cell-free dna [cfdna] significant progression-free survival updated progression-free survival expanded pathway-altered subgroup progression-free survival improvement her2-negative metastatic progression-free survival analysis original pathway-altered subgroup progression-free survival event median progression-free survival joint hormone receptor progression-free survival results progression-free survival benefit originally identified pathway-altered advanced er-positive metastatic breast cancers pathway-altered subgroup assigned pan-akt inhibitor capivasertib locally advanced setting oestrogen receptor-positive

Social Networks {πŸ‘}(6)

External Links {πŸ”—}(77)

Analytics and Tracking {πŸ“Š}

  • Google Analytics
  • Google Analytics 4
  • Google Tag Manager

Libraries {πŸ“š}

  • jQuery
  • jQuery module (jquery-3.6.0)
  • Zoom.js

Emails and Hosting {βœ‰οΈ}

Mail Servers:

  • nihcesxway.hub.nih.gov
  • nihcesxway2.hub.nih.gov
  • nihcesxway3.hub.nih.gov
  • nihcesxway4.hub.nih.gov
  • nihcesxway5.hub.nih.gov

Name Servers:

  • dns1-ncbi.ncbi.nlm.nih.gov
  • dns2-ncbi.ncbi.nlm.nih.gov
  • lhcns1.nlm.nih.gov
  • lhcns2.nlm.nih.gov

CDN Services {πŸ“¦}

  • Ncbi

3.88s.